Zoetis Inc. (NYSE:ZTS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. BofA Downgrades Zoetis (ZTS) to Neutral, Cuts Price Target Budimir Jevtic/Shutterstock.com On December 15, BofA downgraded Zoetis Inc. (NYSE:ZTS) to Neutral from Buy and lowered its price target to $135 from $165. In other news, on December 5, Zoetis Inc. (NYSE:ZTS) announced that Health Canada approved Portela™ (relfovetmab injection) for the relief of pain linked to osteoarthritis, or OA, in cats. Portela is d ...

Zoetis Inc. (NYSE:ZTS) is included among the 15 Dividend Stocks with Low Payout Ratios and Strong Upside. Zoetis (ZTS) Positioned Within Morgan Stanley’s 2026 Healthcare Playbook Budimir Jevtic/Shutterstock.com On December 18, Morgan Stanley lowered its price target on Zoetis Inc. (NYSE:ZTS) to $160 from $175 and kept an Overweight rating. In its year-ahead outlook, the firm said healthcare technology and providers offer an “attractive backdrop for alpha-generation opportunities” in 2026. Managed care i ...